Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst’s Next-Generation Factor VIIa Product CB 813d
24 mai 2016 08h30 HE
|
Catalyst Biosciences, Inc.
- Companies Committed to Establishing Manufacturing Capabilities for Next-Generation Factor VIIa CB 813d -- Catalyst Plans to Initiate Clinical Pivotal Trial in Hemophilia A and B “Inhibitor” Patients...